REG - Genflow Biosciences - New Research Collaboration

Genflow BiosciencesAnnouncement

29/03/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220329:nRSc3107Ga&default-theme=true

RNS Number : 3107G  Genflow Biosciences PLC  29 March 2022

 

PRESS RELEASE

29 March 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

 

New Research Collaboration with the University of Rochester's Aging Research
Center

Opportunity to Demonstrate the Reversal of the Aging Process in Liver Tissue

Genflow (LSE: GENF) is pleased to announce it has commenced a scientific
research collaboration with the University of Rochester's Aging Research
Center (RoAR). This collaboration will initially research the potential of
Sirtuin-6 ("SIRT6") in reversing the aging process in liver tissue. This is
the first step towards a true rejuvenation gene therapy across a range of
tissues.

RoAR is one of the world's pre-eminent age research facilities. The
collaborative research will be spearheaded by a member of the Company's
scientific advisory board, Dr Vera Gorbunova, who is also a co-director of
RoAR and an internationally acclaimed leading scientist in the areas of DNA
repair and the aging process.  Dr Gorbunova has received awards from The
Ellison Medical Foundation, The Glenn Foundation, American Federation for
Aging Research and the National Institute of Health.

 

The SIRT6 gene variant found in centenarians (people aged more than 100 years
old) has previously demonstrated significant capabilities in epigenetic tissue
rejuvenation. The ability of SIRT6 to act on the rejuvenation of cells is a
significant finding, indicative of the SIRT6 gene mutation's potential to not
just halt the aging process, but to reverse it.

While the research collaboration will initially explore the ability of gene
therapy for the rejuvenation of the liver, it could have significant
implications beyond liver tissue and may indicate SIRT6's potential across a
range of tissue rejuvenation and, for longevity research, more widely. The
data obtained from the collaboration will support the pre-clinical trials
Genflow is undertaking and will expedite its development of gene therapies.

Genflow is a UK-based biotechnology company focused on longevity and the
development of therapies to counteract the effects of aging and diseases
associated with advanced age. It is the first longevity biotechnology company
to list in Europe and seeks to be a reference company in the European
longevity sector.

In the near term, this distinguished collaboration will provide the Company
with a deeper presence in, and exposure to, the US. The US longevity sector
has gained enormous attention and traction in recent years. High profile Ultra
Net Worths have a keen interest in this area and prominent deals in the sector
attracted investment capital of over $3bn last year.

Dr Eric Leire, Founder and CEO of Genflow, said: "We are privileged to be
collaborating with the Rochester Aging Research Center (RoAR) to accelerate
and enable bringing a novel gene therapy for not only improving healthy aging
to the clinic and patients, but also offering the opportunity of epigenetic
tissue rejuvenation. The preliminary data from the Gorbunova and Seluanov
Laboratory at the University of Rochester is a promising indication of the
centenarian SIRT6 gene mutation's significant capabilities in the longevity
field.

"We now have the opportunity to demonstrate that SIRT6 can go beyond halting
or stopping the aging process but can also reverse it. In effect, we seek to
demonstrate that you can take an old liver and make it young again - this is
the essence of the epigenetic tissue rejuvenation we are exploring, and it has
the potential to be the basis of a revolutionary gene therapy."

 

For further information please contact:

 Genflow Biosciences Plc
 Dr Eric Leire                       via Tancredi +44 203 434 2330

 Chief Executive
 Clear Capital Markets Ltd
 Corporate Broker                    +44 203 869 6086

 Jonathan Critchley                  +44 203 897 0981

 Keith Swann
 Tancredi Intelligent Communication

 Media Relations
 Salamander Davoudi                  +44 7957 549 906

 Helen Humphrey                      +44 7449 226 720

 Benedetta Negri da Oleggio          +44 7838 029 970

                                     genflowbio@tancredigroup.com

 

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno-associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

About Rochester Aging Research (RoAR) Center and The University of Rochester
Aging Institute

The Rochester Aging Research (RoAR) Center's mission is to promote vitality in
aging by transforming care and communities through discovery, learning,
collaboration and innovation.

The University of Rochester Aging Institute (URAI) is a university-wide
initiative that integrates existing aging-related strengths and expertise,
spanning a myriad of departments, schools and research centers across
campuses, including research, patient care, education and community outreach.

To learn more visit:
www.urmc.rochester.edu/university-of-rochester-aging-institute/
(http://www.urmc.rochester.edu/university-of-rochester-aging-institute/)

 

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBVLLLLXLBBBX